Literature DB >> 21149612

Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury.

Yang Zhou1, Daniel J Schneider, Eva Morschl, Ling Song, Mesias Pedroza, Harry Karmouty-Quintana, Thuy Le, Chun-Xiao Sun, Michael R Blackburn.   

Abstract

Adenosine is an extracellular signaling molecule that is generated in response to cell injury where it orchestrates tissue protection and repair. Whereas adenosine is best known for promoting anti-inflammatory activities during acute injury responses, prolonged elevations can enhance destructive tissue remodeling processes associated with chronic disease states. The generation of adenosine and the subsequent activation of the adenosine 2B receptor (A(2B)R) is an important processes in the regulation of both acute and chronic lung disease. The goal of this study was to examine the contribution of the A(2B)R in models of bleomycin-induced lung injury that exhibit varying degrees of acute and chronic injury. Intratracheal bleomycin exposure results in substantial acute lung injury followed by progressive fibrosis. In this model, genetic removal of the A(2B)R resulted in enhanced loss of barrier function and increased pulmonary inflammation, with few differences in indexes of pulmonary fibrosis. These results support an anti-inflammatory role for this receptor in this model of acute lung injury. In contrast, systemic exposure of mice to bleomycin resulted in modest acute lung injury together with progressive pulmonary fibrosis. In this model, the effects of A(2B)R removal on acute lung injury were negligible; however, there were substantial reductions in pulmonary fibrosis, supporting a profibrotic role for this receptor. A(2B)R-dependent regulation of IL-6 production was identified as a potential mechanism involved in the diminished pulmonary fibrosis seen in A(2B)R knockout mice exposed to i.p. bleomycin. These studies highlight the distinct roles of A(2B)R signaling during acute and chronic stages of lung injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149612      PMCID: PMC3607290          DOI: 10.4049/jimmunol.1002907

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung.

Authors:  P J Sime; Z Xing; F L Graham; K G Csaky; J Gauldie
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

3.  Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury.

Authors:  Jonathan B Volmer; Linda F Thompson; Michael R Blackburn
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

Review 4.  Lung inflammation and fibrosis.

Authors:  P A Ward; G W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

5.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.

Authors:  Kevin K Kim; Matthias C Kugler; Paul J Wolters; Liliane Robillard; Michael G Galvez; Alexis N Brumwell; Dean Sheppard; Harold A Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

6.  A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury.

Authors:  Chun-Xiao Sun; Hays W Young; Jose G Molina; Jonathan B Volmer; Jurgen Schnermann; Michael R Blackburn
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

7.  Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis.

Authors:  Bing Ma; Michael R Blackburn; Chun Geun Lee; Robert J Homer; Wei Liu; Richard A Flavell; Lynn Boyden; Richard P Lifton; Chun-Xiao Sun; Hays W Young; Jack A Elias
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury.

Authors:  Chun-Xiao Sun; Hongyan Zhong; Amir Mohsenin; Eva Morschl; Janci L Chunn; Jose G Molina; Luiz Belardinelli; Dewan Zeng; Michael R Blackburn
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

9.  Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice.

Authors:  Janci L Chunn; Jose G Molina; Tiejuan Mi; Yang Xia; Rodney E Kellems; Michael R Blackburn
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

10.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

View more
  62 in total

1.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

2.  Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury.

Authors:  Tobias Eckle; Emily M Kewley; Kelley S Brodsky; Eunyoung Tak; Stephanie Bonney; Merit Gobel; Devon Anderson; Louise E Glover; Ann K Riegel; Sean P Colgan; Holger K Eltzschig
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

Review 3.  Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis.

Authors:  David Lu; Paul A Insel
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-18       Impact factor: 4.249

Review 4.  The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation.

Authors:  Jonathan M Bekisz; Christopher D Lopez; Carmen Corciulo; Aranzazu Mediero; Paulo G Coelho; Lukasz Witek; Roberto L Flores; Bruce N Cronstein
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

5.  HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.

Authors:  Kemly Philip; Tingting Weng Mills; Jonathan Davies; Ning-Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G Molina; Javier Amione-Guerra; Neeraj Sinha; Ashrith Guha; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2017-07-12       Impact factor: 5.191

Review 6.  A2 adenosine receptors and vascular pathologies.

Authors:  Hillary A Johnston-Cox; Milka Koupenova; Katya Ravid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

7.  Alveolar Epithelial A2B Adenosine Receptors in Pulmonary Protection during Acute Lung Injury.

Authors:  Sandra Hoegl; Kelley S Brodsky; Michael R Blackburn; Harry Karmouty-Quintana; Bernhard Zwissler; Holger K Eltzschig
Journal:  J Immunol       Date:  2015-07-17       Impact factor: 5.422

8.  Evaluating the NET influence of inflammation on pneumonia biology.

Authors:  Lee J Quinton
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

9.  Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension.

Authors:  Harry Karmouty-Quintana; Kemly Philip; Luis F Acero; Ning-Yuan Chen; Tingting Weng; Jose G Molina; Fayong Luo; Jonathan Davies; Ngoc-Bao Le; Isabelle Bunge; Kelly A Volcik; Thanh-Thuy T Le; Richard A Johnston; Yang Xia; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2014-10-15       Impact factor: 5.191

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.